Published on 6 Oct 2024 on GuruFocus.com · via Yahoo Finance
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue...
Total Revenue: $65 million, a 10% increase year-over-year.UDENYCA Revenue: $50.9 million, a 19% increase quarter-over-quarter and a 60% increase over Q2 2023.LOQTORZI Revenue: $3.8 million, nearly doubled from $2 million in Q1.Net Loss: $12.99 million, or $0.11 per diluted share, compared to a net loss of $42.99 million, or $0.49 per diluted share in Q2 2023.Non-GAAP Net Loss: $16.4 million, or $0.14 per diluted share, compared to $32.89 million, or $0.38 per diluted share in Q2 2023.Cash and Cash Equivalents: $159.2 million as of June 30, 2024, compared to $117.7 million at year-end 2023.Cost of Goods Sold: $28.4 million, up from $24.8 million in Q2 2023.R&D Expense: $22 million, a 6% decrease from Q2 2023.SG&A Expense: $35.2 million, a 22% decrease from Q2 2023.Interest Expense: $5.3 million, a 46% decrease from Q2 2023.
Warning! GuruFocus has detected 5 Warning Signs with CHRS.